Mariken Dinnissen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mariken Dinnissen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Andrea Dietrich
Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
3 shared publications- Pieter J. Hoekstra
Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
3 shared publications - Andrea Dietrich
Department of Child and Adolescent Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
2 shared publications Anne M. Verhallen
Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2 shared publicationsBarbara J. van Den Hoofdakker
Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2 shared publications- Barbara J. van Den Hoofdakker
Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Challenges of Recruiting Children and Adolescents Into a Randomized Controlled Risperidone Discontinuation Trial
Background: Randomized controlled trials (RCTs) are essential for evaluating treatment efficacy and safety, but recruitment is often challenging. This study investigated barriers to enrollment in a 4-center RCT examining discontinuation of long-term risperidone treatment in children and adolescents and provides recommendations to improve recruitment in future studies. Methods: To identify clinician-related and patient/parent-related barriers, we recorded all screening and recruitment steps completed in our lead center, as well as reasons for non-eligibility or nonparticipation. Organizational barriers were evaluated based on experiences across all 4 participating centers. Results: A total of 1008 patients were pre-screened, of whom 39.8% seemed to be still receiving risperidone treatment. Of these, 56.5% met our inclusion criteria. Among eligible patients, 60.1% were informed about the study, and 10.8% provided informed consent. Approximately 40% of eligible patients were not invited to participate. Patient-related and parent-related barriers accounted for 50% of nonparticipation, primarily due to preferences for continued risperidone treatment (36.6%) or immediate discontinuation (9%), practical barriers (15.7%), and objections to aspects of the study protocol (12.7%). Organizational barriers included insufficient facilitation and integration of research within participating centers. Conclusions: The main barriers to recruitment were clinician gatekeeping, treatment preferences, and the burden of study participation. Additional challenges included restrictive inclusion and exclusion criteria and insufficient integration of research in clinical practice. We recommend strengthening the integration of research in clinical settings, educating clinicians and patients/parents about RCTs, minimizing participant burden, and considering more pragmatic study designs that accommodate treatment preferences.
- 6 November 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Open AccessChallenges of Recruiting Children and Adolescents Into a Randomized Controlled Risperidone Discontinuation Trial
Background: Randomized controlled trials (RCTs) are essential for evaluating treatment efficacy and safety, but recruitment is often challenging. This study investigated barriers to enrollment in a 4-center RCT examining discontinuation of long-term risperidone treatment in children and adolescents and provides recommendations to improve recruitment in future studies. Methods: To identify clinician-related and patient/parent-related barriers, we recorded all screening and recruitment steps completed in our lead center, as well as reasons for non-eligibility or nonparticipation. Organizational barriers were evaluated based on experiences across all 4 participating centers. Results: A total of 1008 patients were pre-screened, of whom 39.8% seemed to be still receiving risperidone treatment. Of these, 56.5% met our inclusion criteria. Among eligible patients, 60.1% were informed about the study, and 10.8% provided informed consent. Approximately 40% of eligible patients were not invited to participate. Patient-related and parent-related barriers accounted for 50% of nonparticipation, primarily due to preferences for continued risperidone treatment (36.6%) or immediate discontinuation (9%), practical barriers (15.7%), and objections to aspects of the study protocol (12.7%). Organizational barriers included insufficient facilitation and integration of research within participating centers. Conclusions: The main barriers to recruitment were clinician gatekeeping, treatment preferences, and the burden of study participation. Additional challenges included restrictive inclusion and exclusion criteria and insufficient integration of research in clinical practice. We recommend strengthening the integration of research in clinical settings, educating clinicians and patients/parents about RCTs, minimizing participant burden, and considering more pragmatic study designs that accommodate treatment preferences.
- 2 August 2024
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 34 (6) , 253-263
Long-Term Effectiveness of Off-Label Risperidone Treatment in Children and Adolescents: A Randomized, Placebo-Controlled Discontinuation Study
Objectives: Risperidone is commonly prescribed off-label in children and adolescents to manage disruptive behavior. This study aimed to investigate continued benefits of risperidone after at least 1 year of treatment and effects of discontinuation on physical health. Methods: Thirty-five youths (aged 6–18 years, intelligence quotient [IQ] >70) who were treated with risperidone for at least 1 year in regular clinical practice receiving outpatient care were randomly assigned to double-blind continuation of risperidone during 16 weeks or continuation for 2 weeks, gradual dose lowering over 6 weeks, and placebo for 8 weeks. Primary outcome was the total Disruptive Behavior (D-total) score of the parent-reported Nisonger Child Behavior Rating Form—Typical IQ (NCBRF-TIQ). Secondary outcome measures were the clinician-rated Clinical Global Impressions—Improvement scale (CGI-I), the parent, child, and teacher-rated Strengths and Difficulties Questionnaire (SDQ), the parent-rated Retrospective Modified Overt Aggression Scale (R-MOAS), and several health parameters (Udvalg for Kliniske Undersøgelser Side Effect Rating Scale [UKU-SERS], dyskinesia, akathisia, parkinsonism, body mass index (BMI), waist circumference, and laboratory outcomes). Mixed models for repeated measures were conducted for continuous outcomes and a chi-square test for the CGI-I. Results: Discontinuation of risperidone, as compared with continuation, was not associated with significant changes in parent-reported disruptive behaviors. However, discontinuation was related to significant deterioration in parent-rated verbal aggression, teacher-rated behavioral functioning, clinician-rated general functioning, and significant improvements in weight, BMI, waist circumference, and glucose, insulin, and prolactin levels. Although 56% of participants in the discontinuation group experienced relapse, causing premature withdrawal from the study, 44% was able to successfully discontinue risperidone. Conclusion: Discontinuation of risperidone was associated with deterioration on some, but not all behavioral measures according to this explorative study. Discontinuation was associated with important health gains. Despite long-term benefits of risperidone, attempts to withdraw risperidone should be undertaken in individual children. This is a crucial step in preventing harm and fostering health.
- 2 August 2024
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 34 (6) , 253-263
Long-Term Effectiveness of Off-Label Risperidone Treatment in Children and Adolescents: A Randomized, Placebo-Controlled Discontinuation Study
Objectives: Risperidone is commonly prescribed off-label in children and adolescents to manage disruptive behavior. This study aimed to investigate continued benefits of risperidone after at least 1 year of treatment and effects of discontinuation on physical health. Methods: Thirty-five youths (aged 6–18 years, intelligence quotient [IQ] >70) who were treated with risperidone for at least 1 year in regular clinical practice receiving outpatient care were randomly assigned to double-blind continuation of risperidone during 16 weeks or continuation for 2 weeks, gradual dose lowering over 6 weeks, and placebo for 8 weeks. Primary outcome was the total Disruptive Behavior (D-total) score of the parent-reported Nisonger Child Behavior Rating Form—Typical IQ (NCBRF-TIQ). Secondary outcome measures were the clinician-rated Clinical Global Impressions—Improvement scale (CGI-I), the parent, child, and teacher-rated Strengths and Difficulties Questionnaire (SDQ), the parent-rated Retrospective Modified Overt Aggression Scale (R-MOAS), and several health parameters (Udvalg for Kliniske Undersøgelser Side Effect Rating Scale [UKU-SERS], dyskinesia, akathisia, parkinsonism, body mass index (BMI), waist circumference, and laboratory outcomes). Mixed models for repeated measures were conducted for continuous outcomes and a chi-square test for the CGI-I. Results: Discontinuation of risperidone, as compared with continuation, was not associated with significant changes in parent-reported disruptive behaviors. However, discontinuation was related to significant deterioration in parent-rated verbal aggression, teacher-rated behavioral functioning, clinician-rated general functioning, and significant improvements in weight, BMI, waist circumference, and glucose, insulin, and prolactin levels. Although 56% of participants in the discontinuation group experienced relapse, causing premature withdrawal from the study, 44% was able to successfully discontinue risperidone. Conclusion: Discontinuation of risperidone was associated with deterioration on some, but not all behavioral measures according to this explorative study. Discontinuation was associated with important health gains. Despite long-term benefits of risperidone, attempts to withdraw risperidone should be undertaken in individual children. This is a crucial step in preventing harm and fostering health.
- Open Access
- 29 December 2020
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 41 (1) , 13-18
Guideline Adherence of Monitoring Antipsychotic Use for Nonpsychotic Indications in Children and Adolescents
Background: Antipsychotics are frequently prescribed to children and adolescents for nonpsychotic indications. Guidelines recommend regularly assessing treatment response and adverse effects and the ongoing need for their use. We aimed to assess adherence to recommendations of available guidelines regarding monitoring antipsychotic use and to test the influence of children's age, sex, intelligence quotient, and diagnosis on adherence. Methods: We reviewed 426 medical records from 26 centers within 3 large Dutch child and adolescent psychiatry organizations, excluding children with schizophrenia, psychosis, mania, or an intelligence quotient below 70. We investigated whether there was regular assessment of treatment response, adverse events (physical and laboratory), and at least annual discussion of the need of continued use. Results: On average, treatment response was assessed in 69.3% of the recommended treatment periods, height in 25.6%, weight in 30.6%, blood pressure in 20.6%, evaluation of adverse events in 19.4%, and cardiometabolic measures in 13.7%; discontinuation and/or continued need was discussed at least annually in 36.2%. Extrapyramidal and prolactin-related adverse effects, waist circumference, glucose, and lipids were rarely investigated. Higher age was associated with lower rates of assessment of treatment response. Most antipsychotics were prescribed long-term. In those children with sufficient documentation of the course of treatment, 57.7% was still using an antipsychotic 3 years after initiation. Conclusions: Our findings indicate insufficient adherence to guideline recommendations for monitoring antipsychotic use in children and adolescents, as well as long duration of use in the majority of children. Especially, older children are at higher risk of receiving suboptimal care.
- 29 December 2020
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 41 (1) , 13-18
Open AccessGuideline Adherence of Monitoring Antipsychotic Use for Nonpsychotic Indications in Children and Adolescents
Background: Antipsychotics are frequently prescribed to children and adolescents for nonpsychotic indications. Guidelines recommend regularly assessing treatment response and adverse effects and the ongoing need for their use. We aimed to assess adherence to recommendations of available guidelines regarding monitoring antipsychotic use and to test the influence of children's age, sex, intelligence quotient, and diagnosis on adherence. Methods: We reviewed 426 medical records from 26 centers within 3 large Dutch child and adolescent psychiatry organizations, excluding children with schizophrenia, psychosis, mania, or an intelligence quotient below 70. We investigated whether there was regular assessment of treatment response, adverse events (physical and laboratory), and at least annual discussion of the need of continued use. Results: On average, treatment response was assessed in 69.3% of the recommended treatment periods, height in 25.6%, weight in 30.6%, blood pressure in 20.6%, evaluation of adverse events in 19.4%, and cardiometabolic measures in 13.7%; discontinuation and/or continued need was discussed at least annually in 36.2%. Extrapyramidal and prolactin-related adverse effects, waist circumference, glucose, and lipids were rarely investigated. Higher age was associated with lower rates of assessment of treatment response. Most antipsychotics were prescribed long-term. In those children with sufficient documentation of the course of treatment, 57.7% was still using an antipsychotic 3 years after initiation. Conclusions: Our findings indicate insufficient adherence to guideline recommendations for monitoring antipsychotic use in children and adolescents, as well as long duration of use in the majority of children. Especially, older children are at higher risk of receiving suboptimal care.
- Open Access
- 12 February 2020
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 29 (12) , 1717-1727
Prescribing antipsychotics in child and adolescent psychiatry: guideline adherence
Antipsychotics are often prescribed to children and adolescents, mostly off-label. We aimed to assess adherence to recommendations of guidelines for antipsychotic prescription. We reviewed 436 medical records from 155 clinicians from 26 clinics within three Dutch child and adolescent psychiatry organizations (n = 398 outpatient, n = 38 inpatient care). We assessed target symptoms, diagnostic process, prior and concomitant treatment, and consideration of contra-indications. Multiple logistic regression assessed the role of age, sex, and psychiatric diagnosis on adherence to three main recommendations: to (1) prescribe antipsychotics only after other treatments proved insufficient, (2) always combine antipsychotics with psychosocial interventions, and (3) not prescribe multiple antipsychotics simultaneously. Most patients received off-label antipsychotics. Main target symptoms were inattention/hyperactivity (25%), aggression (24%), and other disruptive behaviors (41%). Most patients underwent diagnostic evaluation before the first prescription; however, screening of contra-indications was low (0.2–19%). About 84% had previously received psychosocial treatment and 48% other psychoactive medication, but 9% had not received any treatment. Notably, only 37% continuously received concomitant psychosocial treatment. Simultaneous use of multiple antipsychotics occurred in 3.2%. Younger children were at higher risk of non-adherence to guideline recommendations regarding prior and concomitant treatment, children with autism spectrum disorder or attention-deficit/hyperactivity disorder more likely not to receive concomitant psychosocial treatment. Sex did not significantly affect adherence. Our findings implicate insufficient adherence to important recommendations regarding antipsychotic use in children and adolescents. Especially younger children are at higher risk of receiving suboptimal care. There is an urgency to consistently offer psychosocial interventions during antipsychotic treatment.
- 12 February 2020
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 29 (12) , 1717-1727
Open AccessPrescribing antipsychotics in child and adolescent psychiatry: guideline adherence
Antipsychotics are often prescribed to children and adolescents, mostly off-label. We aimed to assess adherence to recommendations of guidelines for antipsychotic prescription. We reviewed 436 medical records from 155 clinicians from 26 clinics within three Dutch child and adolescent psychiatry organizations (n = 398 outpatient, n = 38 inpatient care). We assessed target symptoms, diagnostic process, prior and concomitant treatment, and consideration of contra-indications. Multiple logistic regression assessed the role of age, sex, and psychiatric diagnosis on adherence to three main recommendations: to (1) prescribe antipsychotics only after other treatments proved insufficient, (2) always combine antipsychotics with psychosocial interventions, and (3) not prescribe multiple antipsychotics simultaneously. Most patients received off-label antipsychotics. Main target symptoms were inattention/hyperactivity (25%), aggression (24%), and other disruptive behaviors (41%). Most patients underwent diagnostic evaluation before the first prescription; however, screening of contra-indications was low (0.2–19%). About 84% had previously received psychosocial treatment and 48% other psychoactive medication, but 9% had not received any treatment. Notably, only 37% continuously received concomitant psychosocial treatment. Simultaneous use of multiple antipsychotics occurred in 3.2%. Younger children were at higher risk of non-adherence to guideline recommendations regarding prior and concomitant treatment, children with autism spectrum disorder or attention-deficit/hyperactivity disorder more likely not to receive concomitant psychosocial treatment. Sex did not significantly affect adherence. Our findings implicate insufficient adherence to important recommendations regarding antipsychotic use in children and adolescents. Especially younger children are at higher risk of receiving suboptimal care. There is an urgency to consistently offer psychosocial interventions during antipsychotic treatment.
- 13 October 2014
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 11 (1) , 111-124
Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that is often accompanied by psychiatric comorbidity. Although there is no medication currently available to treat the core symptoms of ASD, risperidone was the first drug to be approved for use in ASD and is still the best established psychopharmacological option for the treatment of irritability and behavioral problems in ASD. This article gives an overview of the pharmacokinetic profile of risperidone and a comprehensive review of treatment studies regarding the use of risperidone in ASD. Ample evidence supports the short-term use of risperidone for treating irritability and behavioral problems in ASD. Risperidone also shows promise in treating symptoms often associated with ASD, such as stereotypical behavior, social difficulties, hyperactivity and cognitive problems. However, several adverse effects have been identified; most are mild or moderate and well manageable, but weight gain and metabolic changes are a considerable concern. Therefore, risperidone should in our view be seen as 'a last resort', only justified for the short-term treatment of serious behavioral problems, which have failed to respond sufficiently to behavioral interventions. Future studies should investigate long-term effects of risperidone and factors that facilitate individual risk-benefit analyses before treatment.
- 13 October 2014
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 11 (1) , 111-124
Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that is often accompanied by psychiatric comorbidity. Although there is no medication currently available to treat the core symptoms of ASD, risperidone was the first drug to be approved for use in ASD and is still the best established psychopharmacological option for the treatment of irritability and behavioral problems in ASD. This article gives an overview of the pharmacokinetic profile of risperidone and a comprehensive review of treatment studies regarding the use of risperidone in ASD. Ample evidence supports the short-term use of risperidone for treating irritability and behavioral problems in ASD. Risperidone also shows promise in treating symptoms often associated with ASD, such as stereotypical behavior, social difficulties, hyperactivity and cognitive problems. However, several adverse effects have been identified; most are mild or moderate and well manageable, but weight gain and metabolic changes are a considerable concern. Therefore, risperidone should in our view be seen as 'a last resort', only justified for the short-term treatment of serious behavioral problems, which have failed to respond sufficiently to behavioral interventions. Future studies should investigate long-term effects of risperidone and factors that facilitate individual risk-benefit analyses before treatment.